Drugs / Beraprost
Beraprost
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01423435 | Aug → Sep 2011 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01443429 | Aug 2011 → Feb 2014 | impaired renal function disease | Toray Industries, Inc | Completed | No outcome recorded |
| Phase 1 | NCT00719758 | Jun → Sep 2008 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT00989963 | Feb 2010 → Sep 2011 | pulmonary arterial hypertension | Lung Biotechnology PBC | Completed | No outcome recorded |
| Phase 2 | NCT00990314 | Nov 2009 → Nov 2013 | pulmonary arterial hypertension | Lung Biotechnology PBC | Completed | No outcome recorded |
| Phase 2 | NCT00792571 | Feb 2009 → Nov 2013 | pulmonary arterial hypertension | Lung Biotechnology PBC | Completed | No outcome recorded |
| Phase 2 | NCT00781885 | Jan 2009 → Sep 2010 | pulmonary arterial hypertension | Lung Biotechnology PBC | Completed | No outcome recorded |
| Phase 2 | NCT02480751 | Oct 2005 → May 2008 | chronic kidney disease | Toray Industries, Inc | Completed | Missed primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01090037 | Mar 2010 → Aug 2014 | chronic renal failure syndrome, glomerular disorder, nephrosclerosis | Toray Industries, Inc | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01908699 | May 2013 → Feb 2019 | pulmonary arterial hypertension | Lung Biotechnology PBC | Completed | No outcome recorded |
| Phase 3 | NCT01458236 | Nov 2011 → Mar 2016 | pulmonary arterial hypertension | Lung Biotechnology PBC | Withdrawn | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03682952 | Feb 2018 → Apr 2019 | chronic renal failure syndrome | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03431649 | Apr → Jul 2017 | pulmonary hypertension | Dr. Soetomo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02786979 | Jul 2010 → Jan 2013 | type 2 diabetes mellitus | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03142360 | Apr 2017 → Apr 2019 | — | Yonsei University | Unknown | No outcome recorded |
| — | NCT01796418 | Mar 2013 → Aug 2014 | diabetic kidney disease | Seoul National University Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2006-12-05 | Kaken Pharmaceutical | Regulatory 第87期中間報告書（2006年4月1日～2006年9月30日） eir-parts.net ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2006-12-05 | Kaken Pharmaceutical | 第87期中間報告書（2006年4月1日～2006年9月30日） eir-parts.net ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beraprost | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03142360 ↗ |
| Known as | Beraprost sodium | “TRK-100STP, a sustained release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening of some parameters of renal filtration...” PMID 25233856 ↗ Sep 201410“Beraprost sodium (BPS) is a prostacyclin analog with vasodilatory and antiplatelet effects.” PMID 24066672 ↗ Sep 2013 “Beraprost sodium (BPS) is an orally active prostacyclin (PGI2) analogue” PMID 26475266 ↗ Oct 2015 “Beraprost Sodium 314d Modified Release Tablets” NCT01458236 ↗ |
| Known as | Beraprost Sodium Modified Release | “with Beraprost Sodium Modified Release (BPS-MR) tablets” NCT00990314 ↗ |
| Known as | Beraprost Sodium Modified Release Tablet, 60mcg | “Beraprost Sodium Modified Release Tablet, 60mcg” NCT00990314 ↗ |
| Known as | Beraprost sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Known as | BPS | “Beraprost sodium (BPS) is a prostacyclin analog with vasodilatory and antiplatelet effects.” PMID 24066672 ↗ Sep 20132“Beraprost sodium (BPS) is an orally active prostacyclin (PGI2) analogue” PMID 26475266 ↗ Oct 2015 “beraprost sodium(BPS)” NCT01443429 ↗ |
| Known as | BPS-MR | “Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)” NCT00989963 ↗1“with Beraprost Sodium Modified Release (BPS-MR) tablets” NCT00990314 ↗ |
| Known as | MDL-201129 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Known as | MDL-201229 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Known as | ML-1129 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Known as | ML-1229 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Known as | Procylin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Known as | TRK-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Known as | TRK-100STP | “TRK-100STP, a sustained release tablet of an orally-active prostacyclin analogue, beraprost sodium, is suggested to suppress worsening of some parameters of renal filtration...” PMID 25233856 ↗ Sep 2014 |
| Known as | TRK-100STP FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL1207745 ↗ |
| Modality | Other / unclassified | “Beraprost sodium (BPS) is a prostacyclin analog with vasodilatory and antiplatelet effects.” PMID 24066672 ↗ Sep 2013 |
| Modality | Small molecule | — CHEMBL1207745 ↗ |
| Route | Oral | “Following randomization, patients will begin taking active drug (60µg) orally twice daily.” NCT00989963 ↗ |